LogicBio Therapeutics

96 articles with LogicBio Therapeutics

• LogicBio Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

  10/5/2020

  LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio), a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery platforms, today announced the closing of its previously announced underwritten public offering of 8,050,000 shares of common stock at a price to the public of $6.00 per share, which includes the exercise in full of the underwriters’ option to purchase additional shares of common stock. The gro

• LogicBio Therapeutics Announces Pricing of Public Offering of Common Stock

  10/1/2020

  LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio), a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery platforms, today announced the pricing of its previously announced underwritten public offering of 7,000,000 shares of common stock at a price to the public of $6.00 per share. Gross proceeds to LogicBio from the offering are expected to be $42.0 million, before deducting underwriting discounts

• LogicBio Therapeutics Announces Proposed Public Offering of Common Stock

  9/30/2020

  LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio), a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery platforms, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering

• LogicBio Therapeutics to Present at the 4th Annual Chardan Virtual Genetic Medicines Conference October 5, 2020

  9/25/2020

  - LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced CEO Fred Chereau will present at the Chardan Virtual Genetic Medicines Conference on Monday, October 5, 2020 at 11 AM, ET. A live audio webcast of the presentation will be available under the “Events and Presentations” section of LogicBio’s website. A replay of the present

• LogicBio Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business UpdatesFDA Clears IND Application for LB-001 for the Treatment of Methylmalonic Acidemia in Pediatric Patients

  8/10/2020

  - LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio or the Company), a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery platforms, today reported financial results for the quarter ended June 30, 2020, provided a business update and announced the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for LB-001 for the treatment of methylmalonic

• LogicBio Therapeutics Announces SUNRISE Phase 1/2 Clinical Design for LB-001 for the Treatment of Methylmalonic Acidemia in Pediatric Patients

  8/10/2020

  – LogicBio’s First IND Clearance Leveraging GeneRide, an In Vivo Homologous Recombination-based Genome Editing Platform – – Enrollment to Start with Patients as Young as 3 Years Old, De-escalating Down to 6 Months old – – Webcast and Conference Call Today at 8 a.m. ET to Discuss LB-001 Update –

• LogicBio Therapeutics to Hold Virtual-Only Annual Meeting of Stockholders - June 05, 2020

  6/5/2020

  LogicBio Therapeutics, Inc., a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, announced that its 2020 Annual Meeting of Stockholders will be held in a virtual-only format due to continued public health concerns related to coronavirus / COVID-19, and to support the health and well-being of our stockholders and other meeting participants.

• LogicBio Therapeutics to Present at the Jefferies Virtual Healthcare Conference

  5/28/2020

  LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio or the Company), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced it will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020 at 8:00 a.m. ET. A live audio webcast of the presentation will be available under the “Events and Presentations” section of LogicBio’s website. A replay of the p

• LogicBio Therapeutics to Present New Data on GeneRide™ Platform and Next Generation Capsid Development Program at the American Society of Gene & Cell Therapy 2020 Annual Meeting

  5/11/2020

  Presentations Highlighting Novel Preclinical Methylmalonic Acidemia Model

• LogicBio Reports First Quarter 2020 Financial Results and Provides Business Updates

  5/11/2020

  LogicBio Therapeutics, Inc., a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, reported financial results for the quarter ended March 31, 2020 and provided a business update.

• ALERT, ROSEN, GLOBAL INVESTOR COUNSEL, Reminds LogicBio Therapeutics, Inc. Investors of Important Deadline in Securities Class Action Commenced by the Firm

  3/28/2020

  Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of LogicBio Therapeutics, Inc. between December 3, 2018 and February 10, 2020, inclusive of the important May 18, 2020 lead plaintiff deadline in the case.

• LOGC LOSS ALERT: ROSEN, A GLOBALLY RECOGNIZED FIRM, Files First Securities Class Action Lawsuit Against LogicBio Therapeutics, Inc. - LOGC

  3/19/2020

  Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of LogicBio Therapeutics, Inc. (NASDAQ: LOGC) between December 3, 2018 and February 10, 2020, inclusive (the "Class Period")

• LogicBio Therapeutics Appoints Mark Enyedy to its Board of Directors

  3/16/2020

  LogicBio Therapeutics, Inc., a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, announced that Mark Enyedy has been appointed to its Board of Directors, effective as of March 17, 2020.

• LogicBio Reports Full Year 2019 Financial Results and Provides Business Updates

  3/16/2020

  LogicBio Therapeutics, Inc., a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, reported financial results and provided a corporate update for the year ended December 31, 2019.

• SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LogicBio Therapeutics, Inc. - LOGC

  2/18/2020

  Pomerantz LLP is investigating claims on behalf of investors of LogicBio Therapeutics, Inc.

• 

  Clinical Catch-Up: February 10-14

  2/17/2020

  It was a very busy week for clinical trial news. Here’s a look.
• 

  FDA Slaps Clinical Hold on LogicBio's Gene Therapy Treatment

  2/11/2020

  The company disclosed late Monday that the U.S. Food and Drug Administration placed a clinical hold on its proposed gene therapy treatment for methylmalonic academia.

• LogicBio Therapeutics Provides Update on FDA Review of Investigational New Drug Application for LB-001 for Methylmalonic Acidemia

  2/10/2020

  LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on the Investigational New Drug (IND) submission for LB-001 for the treatment of methylmalonic acidemia (MMA) pending the resolution of certain clinical and nonclinical questions.

• LogicBio Therapeutics Announces Collaboration with Takeda to Develop New Genome Editing Candidate LB-301 for the Treatment of Crigler-Najjar Syndrome

  1/10/2020

  LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients today announced a research collaboration with Takeda Pharmaceutical Company Limited (Takeda) to further develop LB-301, an investigational therapy using LogicBio’s proprietary, promoterless, nuclease-free genome editing technology, GeneRide™, for the treatment of Crigler-Najjar syndrome.

• LogicBio Therapeutics Announces Submission of Investigational New Drug Application (IND) for LB-001 for Methylmalonic Acidemia (MMA) and Highlights Key Corporate Milestones

  1/10/2020

  LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to initiate a Phase 1/2 trial of LB-001,